- Home
- BLNK vs ALDX Comparison
BLNK vs ALDX Comparison
Compare BLNK & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLNK | ALDX |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 124.9M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BLNK | ALDX |
|---|---|---|
| Price | $0.56 | $1.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.33 | ★ $5.50 |
| AVG Volume (30 Days) | 2.1M | ★ 2.1M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $1.07 |
| 52 Week High | $2.65 | $6.18 |
Technical Indicators
Market Signals| Indicator | BLNK | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 35.43 | 40.20 |
| Support Level | $0.54 | $1.49 |
| Resistance Level | $0.72 | $1.91 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 14.07 | 11.83 |
Price Performance
Historical ComparisonAbout BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from the U.S.A.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.